OBJECTIVES: Antidepressants is one of the most prescribed class of drugs in the US. The AWP does not represent the drug acquisition cost, but it is one of the most commonly used benchmarks for drug reimbursement. This study assessed the trends in average wholesale prices (AWP) at market entry of antidepressant drugs approved by the FDA and marketed in the US as of October 31, 2016. METHODS: Regulatory information was derived from the FDA website. Average wholesale prices (AWP) per unit at market entry were derived from the RedBook (Truven Health Analytics, Inc.). The AWP history was collected from approval to October 31, 2016. The FDA daily-defined dosage (DDD) for adult patients was obtained from FDA-approved labels. The AWP per DDD, 30 DDD and year were calculated. Prices were adjusted for inflation using the consumer price index (CPI). Descriptive statistics were performed in the study. RESULTS: FDA listed 56 approved antidepressant drugs as of October 2016. There were 20 antidepressant drugs approved by FDA in 1980s, 15 in 1990s, 14 in the 2000s, and 7 in the period 2010-2016. The median AWP per DDD at market entry was $4.02(range=$0.28- $58.27) in the 1980s, $10.75 (range=$1.04 -$37.35) in the 1990s, $24.96(range=$4.54 - $84.39) in the 2000s, and $25.38 (range=$8.67-$149.33) in the period 2010-2016. The median CPI-adjusted AWP per DDD of antidepressant drugs at market increased in average $0.7 per year. CONCLUSIONS: The pharmaceutical companies’ inflation-adjusted listed prices at market entry increased 6.6 times over the period of analysis. Prices of marketed antidepressant drugs also increased faster than the inflation.